Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produce... Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.29 | 181.25 | 0.16 | 0.495 | 0.06 | 767 | 0.40625489 | CS |
| 4 | 0 | 0 | 0.45 | 0.59 | 0.0031 | 1095 | 0.34525861 | CS |
| 12 | -0.05 | -10 | 0.5 | 0.845 | 0.001 | 1598 | 0.29944722 | CS |
| 26 | 0.3 | 200 | 0.15 | 0.845 | 0.001 | 1367 | 0.26911195 | CS |
| 52 | -1.45 | -76.3157894737 | 1.9 | 1.9 | 0.0001 | 1852 | 0.67943645 | CS |
| 156 | -8.81 | -95.1403887689 | 9.26 | 9.26 | 0.0001 | 6716 | 1.8158802 | CS |
| 260 | -8.81 | -95.1403887689 | 9.26 | 9.26 | 0.0001 | 6629 | 1.8158802 | CS |
baltimorebullet
2分前
sctts
12分前
theorysuit
48分前
theorysuit
52分前
Ribo
54分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。